$INTS
Intensity Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Shelton, CT
INTS chart
What traders are saying about $INTS
Latest postsIntensity Therapeutics, Inc. news
- Intensity Therapeutics, Inc. Estimates – NASDAQ:INTS
TradingView ·
- Intensity reports data from Cohort A in the INVINCIBLE-4 Study
TipRanks ·
- Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
Yahoo Finance ·
- INT230-6 shows 71% complete response in early-s...
Pluang ·
- INTS Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Misses EPS Estimate - Balance Sheet Strength
https://www.dars.gov.et/ ·
- Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary
app.moby.co ·
- Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript
fool.com ·
- Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Yahoo Finance ·
- Soft Tissue Sarcoma Market Set for Significant Growth at a CAGR of 7.9% During the Forecast Period (2026-2036), Driven by Novel Therapies and Expanding Treatment Landscape | DelveInsight
Yahoo Finance ·
- Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)
Yahoo Finance ·
Intensity Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$11.6M | -$16.3M | -$10.5M | -$7.6M |
| Diluted EPS | $-8.56 | $-29.24 | $-1.38 | $-2.22 |
| Total assets (year end) | $14.1M | $4.8M | $17.3M | $1.8M |
| Cash and equivalents (year end) | $11.9M | $2.6M | $8.6M | $1.3M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Intensity Therapeutics, Inc.
- Ticker
- INTS (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Shelton, CT
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1567264
Frequently asked questions
What exchange is Intensity Therapeutics, Inc. listed on?
Intensity Therapeutics, Inc. trades on the Nasdaq under the ticker symbol INTS.
What industry is Intensity Therapeutics, Inc. in?
Intensity Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Intensity Therapeutics, Inc. headquartered?
Intensity Therapeutics, Inc.'s business address on file with the SEC is in Shelton, CT.
When does Intensity Therapeutics, Inc.'s fiscal year end?
Intensity Therapeutics, Inc.'s fiscal year ends on December 31.